Super-Fast Novolog performs better in Type 1 Diabetes

Super-Fast Novolog performs better in Type 1 Diabetes

Faster-acting novolog lowers A1c, 1 hour and 2 hours postprandial glucose more than conventional novolog. About 1,000 type 1 diabetes participants were followed for 26 weeks. Adverse events were overall similar between the two insulins.

Faster-acting novolog would provide more flexibility and glycemic control to a patient who injects insulin immediately after meals.

Based on these data I would anticipate FDA-approval of the super-fast novolog.

GT

Read more →

要查看或添加评论,请登录

Gerti Tashko, MD的更多文章

社区洞察

其他会员也浏览了